Winter Rains Revive Iraq's Famed Marshlands

In this Tuesday, April 23, 2019, photo, a farmer stands near a water pump on his farm in Youssifiyah, Iraq. AP
In this Tuesday, April 23, 2019, photo, a farmer stands near a water pump on his farm in Youssifiyah, Iraq. AP
TT

Winter Rains Revive Iraq's Famed Marshlands

In this Tuesday, April 23, 2019, photo, a farmer stands near a water pump on his farm in Youssifiyah, Iraq. AP
In this Tuesday, April 23, 2019, photo, a farmer stands near a water pump on his farm in Youssifiyah, Iraq. AP

Black buffaloes wade through the waters of Iraq's Mesopotamian marshes, leisurely chewing on reeds. After years of drought, winter rains have brought some respite to herders and livestock in the famous wetlands.

Listed as a UNESCO World Heritage Site, the marshes were parched and dusty last summer by drought in the climate-stressed country and by reduced flow from the Tigris and Euphrates rivers due to dams built upstream in Turkey and Iran.

Winter brings seasonal rains, offering relief in marshes like those of Huwaizah -- which straddles the border with Iran -- and Chibayish, located in nearby Dhi Qar province.

Among the reeds of Chibayish, buffalo farmer Rahim Daoud now uses a stick to punt his boat across an expanse of water.

"This summer, it was dirt here; there was no water," said the 58-year-old. "With the rain that has fallen, the water level has risen."

Last summer, AFP photographers travelled to the Huwaizah and Chibayish marshes to document the disappearance of large portions of the wetlands, observing vast expanses of dry and cracked soil dotted with yellowed shrubs.

In October, an official in the impoverished rural province of Dhi Qar told AFP that in the previous six months, 1,200 families had left the marshes and other agricultural areas of southern Iraq and more than 2,000 buffaloes had died.

Iraq has faced three consecutive years of severe drought and scorching heat, with temperatures regularly exceeding 50 degrees Celsius (122 Fahrenheit) during the summer of 2022.

"There is a gradual improvement," Hussein al-Kenani said after the recent rains.

He heads the governmental center in charge of protecting the wetlands and said rainwater collected in canals and rivers has been redirected to the marshes.

"The water level in Chibayish's swamps has increased by more than 50 centimeters (20 inches) compared with December and by more than 30 centimeters for the Huwaizah swamps," Kenani said.

In July, the UN Food and Agriculture Organization deplored the "unprecedented low water levels" in the marshes, highlighting "the disastrous impact" for more than 6,000 families, whose buffaloes and livelihoods were being lost.

The relief of rainfall early this month was welcomed by the UN agency, which noted in a statement that in the Chibayish region "salinity levels decreased" to the point that people and animals could again drink the water.

"This has had a great positive impact, especially on buffalo herders," it said.



Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”